Beam Therapeutics Stock Probability of Future Stock Price Finishing Under 22.14
| BEAM Stock | USD 29.13 1.07 3.54% |
Beam |
Beam Therapeutics Target Price Odds to finish below 22.14
The tendency of Beam Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 22.14 or more in 90 days |
| 29.13 | 90 days | 22.14 | about 7.32 |
Based on a normal probability distribution, the odds of Beam Therapeutics to drop to $ 22.14 or more in 90 days from now is about 7.32 (This Beam Therapeutics probability density function shows the probability of Beam Stock to fall within a particular range of prices over 90 days) . Probability of Beam Therapeutics price to stay between $ 22.14 and its current price of $29.13 at the end of the 90-day period is about 91.2 .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.76 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Beam Therapeutics will likely underperform. Additionally Beam Therapeutics has an alpha of 0.1566, implying that it can generate a 0.16 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Beam Therapeutics Price Density |
| Price |
Predictive Modules for Beam Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Beam Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Beam Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Beam Therapeutics is not an exception. The market had few large corrections towards the Beam Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Beam Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Beam Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.16 | |
β | Beta against Dow Jones | 2.76 | |
σ | Overall volatility | 1.92 | |
Ir | Information ratio | 0.08 |
Beam Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Beam Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Beam Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Beam Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 377.71 M. Net Loss for the year was (132.53 M) with loss before overhead, payroll, taxes, and interest of (250.67 M). | |
| Beam Therapeutics currently holds about 1.09 B in cash with (149.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9. | |
| Beam Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from prnewswire.com: Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3 |
Beam Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Beam Stock often depends not only on the future outlook of the current and potential Beam Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Beam Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 77.2 M | |
| Cash And Short Term Investments | 1.2 B |
Beam Therapeutics Technical Analysis
Beam Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Beam Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Beam Therapeutics. In general, you should focus on analyzing Beam Stock price patterns and their correlations with different microeconomic environments and drivers.
Beam Therapeutics Predictive Forecast Models
Beam Therapeutics' time-series forecasting models is one of many Beam Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Beam Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Beam Therapeutics
Checking the ongoing alerts about Beam Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Beam Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Beam Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 377.71 M. Net Loss for the year was (132.53 M) with loss before overhead, payroll, taxes, and interest of (250.67 M). | |
| Beam Therapeutics currently holds about 1.09 B in cash with (149.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9. | |
| Beam Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from prnewswire.com: Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3 |
Check out Beam Therapeutics Backtesting, Beam Therapeutics Valuation, Beam Therapeutics Correlation, Beam Therapeutics Hype Analysis, Beam Therapeutics Volatility, Beam Therapeutics History as well as Beam Therapeutics Performance. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share 4.273 | Quarterly Revenue Growth (0.17) | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.